Items where authors include "Werfel, T."
Article
Zuberbier, T. orcid.org/0000-0002-1466-8875, Abdul Latiff, A., Aggelidis, X. orcid.org/0000-0003-1715-3022 et al. (105 more authors) (2023) A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative. Clinical and Translational Allergy, 13 (9). e12299. ISSN 2045-7022
Zuberbier, T. orcid.org/0000-0002-1466-8875, Beck, L.A., Bedbrook, A. et al. (12 more authors) (2023) Developing integrated care pathways for atopic dermatitis—challenges and unmet needs. Clinical and Translational Allergy, 13 (3). e12236. ISSN 2045-7022
Ring, J., Worm, M., Wollenberg, A. et al. (35 more authors) (2021) Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 35 (6). e362-e365. ISSN 0926-9959
Thyssen, J.P., Vestergaard, C., Barbarot, S. et al. (32 more authors) (2021) European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 35 (5). e308-e311. ISSN 0926-9959
Wollenberg, A., Christen‐Zäch, S., Taieb, A. et al. (24 more authors) (2020) ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 34 (12). pp. 2717-2744. ISSN 0926-9959
Wollenberg, A., Flohr, C., Simon, D. et al. (30 more authors) (2020) European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 34 (6). e241-e242. ISSN 0926-9959
Luger, T., Boguniewicz, M., Carr, W. et al. (22 more authors) (2015) Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 26 (4). pp. 306-315. ISSN 0905-6157